Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 GlobeNewswire - Mon Apr 13, 7:00AM CDT

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium GlobeNewswire - Tue Apr 7, 7:00AM CDT

CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Apr 2, 3:05PM CDT

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors GlobeNewswire - Wed Apr 1, 3:05PM CDT

CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 GlobeNewswire - Thu Mar 19, 3:05PM CDT

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference GlobeNewswire - Tue Mar 3, 7:00AM CST

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 2, 3:05PM CST

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics: Q4 Earnings Snapshot AP - Thu Feb 26, 6:30AM CST

Akebia Therapeutics: Q4 Earnings Snapshot

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights GlobeNewswire - Thu Feb 26, 6:00AM CST

Q4 2025 net product revenues of  $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant...

AKBA : 1.4700 (+5.00%)
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights GlobeNewswire - Thu Feb 19, 7:00AM CST

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December...

AKBA : 1.4700 (+5.00%)

Barchart Exclusives

Ignore the Anthropic Panic and Keep Buying Palantir Stock, Says Wedbush Barchart - Mon Apr 13, 3:53PM CDT
Wedbush urges investors to tune out the Anthropic noise and keep buying Palantir, betting on its strong AI moat and solid fundamentals. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.